Publ. indicates publication date; pts., patients; FU, follow-up; UK, United Kingdom; UKNCRI, United Kingdom National Cancer Research Institute; MEC, MOPPEBVCAD (mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine); VAPEC, doxorubicin, cyclophosphamide, etoposide, vincristine, bleomycin, and prednisolone; BEA, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone; esc., escalated; FFS, failure-free survival; LMM, large mediastinal mass.